# The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment

> **NCT03855007** · PHASE4 · COMPLETED · sponsor: **Qilu Hospital of Shandong University** · enrollment: 400 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Iguratimod
- **DRUG:** MTX
- **DRUG:** HCQ
- **DRUG:** Pred

## Key facts

- **NCT ID:** NCT03855007
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-10-31
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03855007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03855007, "The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03855007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*